Format
Sort by

Send to

Choose Destination

Search results

Items: 1 to 20 of 32

1.

Association of Hepatitis C Virus Infection With CD4/CD8 Ratio in HIV-Positive Women.

Kuniholm MH, OʼBrien TR, Prokunina-Olsson L, Augenbraun M, Plankey M, Karim R, Sarkar M, French AL, Pierce C, Strickler HD, Anastos K.

J Acquir Immune Defic Syndr. 2016 Jun 1;72(2):162-70. doi: 10.1097/QAI.0000000000000928.

2.

Reply: Subgroup Differences in Response to 8 Weeks of Ledipasvir/Sofosbuvir for Chronic Hepatitis C.

O'Brien TR, Pfeiffer RM.

Open Forum Infect Dis. 2015 Apr 20;2(2):ofv057. doi: 10.1093/ofid/ofv057. eCollection 2015 Apr. No abstract available.

3.

Interferon Lambda 4 Genotype Is Not Associated with Recurrence of Oral or Genital Herpes.

Lang Kuhs KA, Kuniholm MH, Pfeiffer RM, Chen S, Desai S, Edlin BR, Peters MG, Plankey M, Sharp GB, Strickler HD, Villacres MC, Quinn TC, Gange SJ, Prokunina-Olsson L, Greenblatt RM, O'Brien TR.

PLoS One. 2015 Oct 2;10(10):e0138827. doi: 10.1371/journal.pone.0138827. eCollection 2015.

4.

Subgroup differences in response to 8 weeks of ledipasvir/sofosbuvir for chronic hepatitis C.

O'Brien TR, Lang Kuhs KA, Pfeiffer RM.

Open Forum Infect Dis. 2014 Dec 13;1(3):ofu110. doi: 10.1093/ofid/ofu110. eCollection 2014 Dec.

5.

IFN-λ4: the paradoxical new member of the interferon lambda family.

O'Brien TR, Prokunina-Olsson L, Donnelly RP.

J Interferon Cytokine Res. 2014 Nov;34(11):829-38. doi: 10.1089/jir.2013.0136. Epub 2014 Apr 30. Review.

6.

IFNL4-ΔG genotype is associated with slower viral clearance in hepatitis C, genotype-1 patients treated with sofosbuvir and ribavirin.

Meissner EG, Bon D, Prokunina-Olsson L, Tang W, Masur H, O'Brien TR, Herrmann E, Kottilil S, Osinusi A.

J Infect Dis. 2014 Jun 1;209(11):1700-4. doi: 10.1093/infdis/jit827. Epub 2013 Dec 23.

7.

Hepatitis C genotype 1 virus with low viral load and rapid virologic response to peginterferon/ribavirin obviates a protease inhibitor.

Wang AS, Pfeiffer RM, Morgan TR, O'Brien TR.

Hepatology. 2014 Jun;59(6):2423-4. doi: 10.1002/hep.26771. Epub 2014 Apr 14. No abstract available.

8.

Association of the IFNL4-ΔG Allele With Impaired Spontaneous Clearance of Hepatitis C Virus.

Aka PV, Kuniholm MH, Pfeiffer RM, Wang AS, Tang W, Chen S, Astemborski J, Plankey M, Villacres MC, Peters MG, Desai S, Seaberg EC, Edlin BR, Strickler HD, Thomas DL, Prokunina-Olsson L, Sharp GB, O'Brien TR.

J Infect Dis. 2014 Feb 1;209(3):350-4. doi: 10.1093/infdis/jit433. Epub 2013 Aug 15.

9.

A variant upstream of IFNL3 (IL28B) creating a new interferon gene IFNL4 is associated with impaired clearance of hepatitis C virus.

Prokunina-Olsson L, Muchmore B, Tang W, Pfeiffer RM, Park H, Dickensheets H, Hergott D, Porter-Gill P, Mumy A, Kohaar I, Chen S, Brand N, Tarway M, Liu L, Sheikh F, Astemborski J, Bonkovsky HL, Edlin BR, Howell CD, Morgan TR, Thomas DL, Rehermann B, Donnelly RP, O'Brien TR.

Nat Genet. 2013 Feb;45(2):164-71. doi: 10.1038/ng.2521. Epub 2013 Jan 6.

10.

HCV RNA levels in a multiethnic cohort of injection drug users: human genetic, viral and demographic associations.

Uccellini L, Tseng FC, Monaco A, Shebl FM, Pfeiffer R, Dotrang M, Buckett D, Busch MP, Wang E, Edlin BR, Marincola FM, O'Brien TR.

Hepatology. 2012 Jul;56(1):86-94. doi: 10.1002/hep.25652. Epub 2012 Jun 1.

11.

Editorial: epidemic-assistance investigations by the centers for disease control and prevention: the first 60 years.

O'Brien TR.

Am J Epidemiol. 2011 Dec 1;174(11):1211-2. doi: 10.1093/aje/kwr336. No abstract available.

12.

IL28B rs12979860 genotype and spontaneous clearance of hepatitis C virus in a multi-ethnic cohort of injection drug users: evidence for a supra-additive association.

Shebl FM, Pfeiffer RM, Buckett D, Muchmore B, Chen S, Dotrang M, Prokunina-Olsson L, Edlin BR, O'Brien TR.

J Infect Dis. 2011 Dec 15;204(12):1843-7. doi: 10.1093/infdis/jir647. Epub 2011 Oct 19.

13.

Interferon-lambda and therapy for chronic hepatitis C virus infection.

Donnelly RP, Dickensheets H, O'Brien TR.

Trends Immunol. 2011 Sep;32(9):443-50. doi: 10.1016/j.it.2011.07.002. Epub 2011 Aug 5. Review.

14.

An IL28B genotype-based clinical prediction model for treatment of chronic hepatitis C.

O'Brien TR, Everhart JE, Morgan TR, Lok AS, Chung RT, Shao Y, Shiffman ML, Dotrang M, Sninsky JJ, Bonkovsky HL, Pfeiffer RM; HALT-C Trial Group.

PLoS One. 2011;6(7):e20904. doi: 10.1371/journal.pone.0020904. Epub 2011 Jul 8.

15.

A functional polymorphism in the epidermal growth factor gene is associated with risk for hepatocellular carcinoma.

Abu Dayyeh BK, Yang M, Fuchs BC, Karl DL, Yamada S, Sninsky JJ, O'Brien TR, Dienstag JL, Tanabe KK, Chung RT; HALT-C Trial Group.

Gastroenterology. 2011 Jul;141(1):141-9. doi: 10.1053/j.gastro.2011.03.045. Epub 2011 Mar 24.

16.

IL28B-genotype testing now and in the era of direct-acting antiviral agents.

Morgan TR, O'Brien TR.

Clin Gastroenterol Hepatol. 2011 Apr;9(4):293-4. doi: 10.1016/j.cgh.2010.12.014. Epub 2010 Dec 23. No abstract available.

17.

HLA-B alleles associate consistently with HIV heterosexual transmission, viral load, and progression to AIDS, but not susceptibility to infection.

Gao X, O'Brien TR, Welzel TM, Marti D, Qi Y, Goedert JJ, Phair J, Pfeiffer R, Carrington M.

AIDS. 2010 Jul 31;24(12):1835-40. doi: 10.1097/QAD.0b013e32833c3219.

18.

Splicing diversity of the human OCLN gene and its biological significance for hepatitis C virus entry.

Kohaar I, Ploss A, Korol E, Mu K, Schoggins JW, O'Brien TR, Rice CM, Prokunina-Olsson L.

J Virol. 2010 Jul;84(14):6987-94. doi: 10.1128/JVI.00196-10. Epub 2010 May 12.

19.

Genome-wide association studies, field synopses, and the development of the knowledge base on genetic variation and human diseases.

Khoury MJ, Bertram L, Boffetta P, Butterworth AS, Chanock SJ, Dolan SM, Fortier I, Garcia-Closas M, Gwinn M, Higgins JP, Janssens AC, Ostell J, Owen RP, Pagon RA, Rebbeck TR, Rothman N, Bernstein JL, Burton PR, Campbell H, Chockalingam A, Furberg H, Little J, O'Brien TR, Seminara D, Vineis P, Winn DM, Yu W, Ioannidis JP.

Am J Epidemiol. 2009 Aug 1;170(3):269-79. doi: 10.1093/aje/kwp119. Epub 2009 Jun 4.

20.

Variants in interferon-alpha pathway genes and response to pegylated interferon-Alpha2a plus ribavirin for treatment of chronic hepatitis C virus infection in the hepatitis C antiviral long-term treatment against cirrhosis trial.

Welzel TM, Morgan TR, Bonkovsky HL, Naishadham D, Pfeiffer RM, Wright EC, Hutchinson AA, Crenshaw AT, Bashirova A, Carrington M, Dotrang M, Sterling RK, Lindsay KL, Fontana RJ, Lee WM, Di Bisceglie AM, Ghany MG, Gretch DR, Chanock SJ, Chung RT, O'Brien TR; HALT-C Trial Group.

Hepatology. 2009 Jun;49(6):1847-58. doi: 10.1002/hep.22877.

Items per page

Supplemental Content

Loading ...
Write to the Help Desk